Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
Pacritinib in CMML
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Douglas Tremblay
- Target Recruit Count
- 26
- Registration Number
- NCT06159491
- Locations
- 🇺🇸
The Mount Sinai Hospital, New York, New York, United States
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT06109064
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
- Conditions
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06105658
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT06085638
A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-01-18
- Target Recruit Count
- 142
- Registration Number
- NCT06014489
- Locations
- 🇳🇱
NL-Leeuwarden-MCL, Leeuwarden, Netherlands
🇳🇱NL-Enschede-MST, Enschede, Netherlands
🇳🇱NL-Eindhoven-MAXIMAMC, Eindhoven, Netherlands
Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 138
- Registration Number
- NCT06004765
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05970822
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Chidamide Plus Azacitidine for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2023-07-25
- Target Recruit Count
- 37
- Registration Number
- NCT05958719
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05955261
- Locations
- 🇺🇸
Rady Children's Hospital-San Diego, San Diego, California, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Servier Affaires Médicales
- Target Recruit Count
- 245
- Registration Number
- NCT05907057
- Locations
- 🇫🇷
CHU Rennes - Hopital Pontchaillou, Rennes, Ille Et Vilaine, France
🇫🇷Institut Paoli Calmettes, Marseille, Bouches-du-Rhône, France
🇮🇹IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - IRST, Meldola, Forli-Cesena, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.